BACKGROUND: GPR7, the endogenous coupled receptor for neuropeptide B and neuropeptide W, is expressed in several regions of the central nervous system, which are involved in the regulation of feeding behavior. GPR7 affects the regulation of energy balance through a mechanism independent of leptin and melanocortin pathways. AIM: Aim of this study was to investigate whether GPR7 gene mutations can be detected in human subjects and, in that event, if they are differently distributed among lean and obese subjects. SUBJECTS AND METHODS: The coding region of GPR7 were sequenced in 150 obese patients and 100 normal-weight unrelated controls. Functional studies of the allelic variants were performed. RESULTS: One genetic GPR7 variant was found (Tyr135Phe - rs33977775) in obese subjects (13.3%) and lean control (25%). Functional studies did not reveal significant differences between the wild type and the Tyr135Phe allelic variants in their NPW-mediated capacity to inhibit forskolin-induced cAMP production. CONCLUSIONS: Screening of GPR7 gene mutations among lean and obese subjects revealed a Tyr135Phe allelic variant that was fairly common in the study population. As indicated by in vitro and in silico studies, this variant is unlikely to cause a functional derangement of the receptor.
BACKGROUND: GPR7, the endogenous coupled receptor for neuropeptide B and neuropeptide W, is expressed in several regions of the central nervous system, which are involved in the regulation of feeding behavior. GPR7 affects the regulation of energy balance through a mechanism independent of leptin and melanocortin pathways. AIM: Aim of this study was to investigate whether GPR7 gene mutations can be detected in human subjects and, in that event, if they are differently distributed among lean and obese subjects. SUBJECTS AND METHODS: The coding region of GPR7 were sequenced in 150 obese patients and 100 normal-weight unrelated controls. Functional studies of the allelic variants were performed. RESULTS: One genetic GPR7 variant was found (Tyr135Phe - rs33977775) in obese subjects (13.3%) and lean control (25%). Functional studies did not reveal significant differences between the wild type and the Tyr135Phe allelic variants in their NPW-mediated capacity to inhibit forskolin-induced cAMP production. CONCLUSIONS: Screening of GPR7 gene mutations among lean and obese subjects revealed a Tyr135Phe allelic variant that was fairly common in the study population. As indicated by in vitro and in silico studies, this variant is unlikely to cause a functional derangement of the receptor.
Authors: B F O'Dowd; M A Scheideler; T Nguyen; R Cheng; J S Rasmussen; A Marchese; R Zastawny; H H Heng; L C Tsui; X Shi Journal: Genomics Date: 1995-07-01 Impact factor: 5.736
Authors: M Tonacchera; P Agretti; A Pinchera; V Rosellini; A Perri; P Collecchi; P Vitti; L Chiovato Journal: J Clin Endocrinol Metab Date: 2000-03 Impact factor: 5.958
Authors: Hirokazu Tanaka; Tetsuo Yoshida; Norimasa Miyamoto; Toshiyuki Motoike; Hiroshi Kurosu; Kenji Shibata; Akihiro Yamanaka; S Clay Williams; James A Richardson; Natsuko Tsujino; Mary G Garry; Michael R Lerner; David S King; Brian F O'Dowd; Takeshi Sakurai; Masashi Yanagisawa Journal: Proc Natl Acad Sci U S A Date: 2003-04-28 Impact factor: 11.205